Oral Antidiabetic Drug Use in the Elderly

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 1996 Dec 1

PMID 8972242

Citations 3

Authors

R BRESSLER

D G Johnson

Affiliations

Soon will be listed here.

Abstract

Non-insulin-dependent diabetes mellitus (NIDDM) is a metabolic disease that is common in the elderly, and is characterised by insulin insufficiency and resistance. Measures such as bodyweight reduction and exercise improve the metabolic defects, but pharmacological therapy is the most frequently used and successful therapy. The sulphonylureas stimulate insulin secretion. Metformin and troglitazone increase glucose disposal and decrease hepatic glucose output without causing hypoglycaemia. Acarbose is a dietary aid that spreads the dietary carbohydrate challenge to endogenous insulin over time. These pharmacological agents, either alone or in combination, should improve blood glucose regulation in patients with NIDDM.

Citing Articles

Update on the treatment of type 2 diabetes mellitus.

Marin-Penalver J, Martin-Timon I, Sevillano-Collantes C, Del Canizo-Gomez F World J Diabetes. 2016; 7(17):354-95.

PMID: 27660695 PMC: 5027002. DOI: 10.4239/wjd.v7.i17.354.

Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.

Scott L, Spencer C Drugs. 2000; 59(3):521-49.

PMID: 10776834 DOI: 10.2165/00003495-200059030-00012.

Troglitazone: a review of its use in the management of type 2 diabetes mellitus.

Plosker G, Faulds D Drugs. 1999; 57(3):409-38.

PMID: 10193691 DOI: 10.2165/00003495-199957030-00014.

References

Noury J, Nandeuil A . Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabete Metab. 1991; 17(1 Pt 2):209-12. View

Logie A, Galloway D, Petrie J . Drug interactions and long-term antidiabetic therapy. Br J Clin Pharmacol. 2012; 3(6):1027-32. PMC: 1428972. DOI: 10.1111/j.1365-2125.1976.tb00353.x. View

Garvey W, Olefsky J, Griffin J, Hamman R, Kolterman O . The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985; 34(3):222-34. DOI: 10.2337/diab.34.3.222. View

Caspary W . Sucrose malabsorption in man after ingestion of alpha-glucosidehydrolase inhibitor. Lancet. 1978; 1(8076):1231-3. DOI: 10.1016/s0140-6736(78)92466-2. View

Leahy J, Cooper H, Deal D, Weir G . Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions. J Clin Invest. 1986; 77(3):908-15. PMC: 423478. DOI: 10.1172/JCI112389. View

Weir G . Which comes first in non-insulin-dependent diabetes mellitus: insulin resistance or beta-cell failure? Both come first. JAMA. 1995; 273(23):1878-9. View

CLARKE B, Campbell I . Long-term comparative trial of glibenclamide and chlorpropamide in diet-failed, maturity-onset diabetics. Lancet. 1975; 1(7901):246-8. DOI: 10.1016/s0140-6736(75)91141-1. View

Hillebrand I, Boehme K, FRANK G, Fink H, Berchtold P . The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: dose-time-response relationships in man. Res Exp Med (Berl). 1979; 175(1):87-94. DOI: 10.1007/BF01851237. View

Holmes B, Heel R, Brogden R, Speight T, Avery G . Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs. 1984; 27(4):301-27. DOI: 10.2165/00003495-198427040-00002. View

10.

Vierhapper H, Waldhausl W . Alpha-glucoside hydrolase inhibition in diabetes. Lancet. 1978; 2(8104-5):1386. DOI: 10.1016/s0140-6736(78)92030-5. View

11.

. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995; 44(11):1249-58. View

12.

Yki-Jarvinen H, Helve E, Koivisto V . Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes. 1987; 36(8):892-6. DOI: 10.2337/diab.36.8.892. View

13.

Berger W, Caduff F, Pasquel M, Rump A . [The relatively frequent incidence of severe sulfonylurea-induced hypoglycemia in the last 25 years in Switzerland. Results of 2 surveys in Switzerland in 1969 and 1984]. Schweiz Med Wochenschr. 1986; 116(5):145-51. View

14.

Ferner R, Chaplin S . The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin Pharmacokinet. 1987; 12(6):379-401. DOI: 10.2165/00003088-198712060-00001. View

15.

WALTON R, Sherif I, Noy G, Alberti K . Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor. Br Med J. 1979; 1(6158):220-1. PMC: 1597843. DOI: 10.1136/bmj.1.6158.220. View

16.

Vigneri R, Goldfine I . Role of metformin in treatment of diabetes mellitus. Diabetes Care. 1987; 10(1):118-22. DOI: 10.2337/diacare.10.1.118. View

17.

Scheen A, Lefebvre P . Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas. Diabetes Res Clin Pract. 1989; 6(4):S33-42; discussion S42-3. DOI: 10.1016/0168-8227(89)90076-4. View

18.

Charles S, Ketelslegers J, Buysschaert M, Lambert A . Hyperglycaemic effect of nifedipine. Br Med J (Clin Res Ed). 1981; 283(6283):19-20. PMC: 1506021. DOI: 10.1136/bmj.283.6283.19. View

19.

Schnack C, Prager R, Winkler J, Klauser R, Schneider B, Schernthaner G . Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care. 1989; 12(8):537-43. DOI: 10.2337/diacare.12.8.537. View

20.

Feinstein A . How good is the statistical evidence against oral hypoglycemic agents?. Adv Intern Med. 1979; 24:71-95. View